Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial

✍ Scribed by Otto Prümmer; Delta-P Study Group

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 657 KB
• Volume: 71
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19930301)71:5<1828::aid-cncr2820710518>3.0.co;2-0

✦ Synopsis

Background. Prolonged therapy with interferon (IFN) may lead to the formation of IFN antibodies.

Methods. Patients with renal cell carcinoma (n = 270) with advanced localized disease were randomized after complete tumor resection to receive treatment with adjuvant recombinant IFN-alpha-2a (rIFN-a2a) (9 X lo6 IU subcutaneously, three times per week for a maximum of 12 months) versus no treatment. Patients (IFN-treated group, 106 patients; control group, 97 patients) were monitored for the presence of rIFN-a2a antibodies.

Results. Of 86 IFN-treated patients observed for more than 2 months, 40 (47%) had IFN-a2a-binding and 25 (29%) had IFN-a2a-neutralizing antibodies developed within a median of 3 and 6 months, respectively. A distinct peak in binding antibody titers occurred at 6-9 months. Therapy-induced neutralizing antibodies were equally reactive with two other recombinant IFN-alpha-2 subtypes but poorly recognized natural IFN-alpha (IFN-a), recombinant IFN-alpha-l/alpha-8, and recombinant IFN-omega-1. The duration of remission and rate of From the